.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Baxter
US Army
Covington
McKinsey
Novartis
Harvard Business School
QuintilesIMS
Chubb
Fish and Richardson

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,056,500

« Back to Dashboard

Which drugs does patent 7,056,500 protect, and when does it expire?


Patent 7,056,500 protects MOVANTIK and is included in one NDA.

This patent has eighteen patent family members in thirteen countries.

Summary for Patent: 7,056,500

Title:Polymer conjugates of opioid antagonists
Abstract: The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of the invention.
Inventor(s): Bentley; Michael David (Huntsville, AL), Roberts; Michael James (Williamsburg, VA), Shen; Xiaoming (Madison, AL), Cheng; Lin (Huntsville, AL)
Assignee: Nektar Therapeutics AL, Corporation (Huntsville, AL)
Application Number:10/274,296
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca PharmsMOVANTIKnaloxegol oxalateTABLET;ORAL204760-001Sep 16, 2014RXYesNo► Subscribe► SubscribeYTREATMENT OF OPIOID-INDUCED CONSTIPATION► Subscribe
Astrazeneca PharmsMOVANTIKnaloxegol oxalateTABLET;ORAL204760-002Sep 16, 2014RXYesYes► Subscribe► SubscribeYTREATMENT OF OPIOID-INDUCED CONSTIPATION► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,056,500

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,662,365Polymer conjugates of opioid antagonists► Subscribe
8,617,530Polymer conjugates of opioid antagonists► Subscribe
8,349,307Polymer conjugates of opioid antagonists► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,056,500

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2002360284► Subscribe
Canada2463938► Subscribe
Cyprus1117608► Subscribe
Denmark2939696► Subscribe
European Patent Office1436012► Subscribe
European Patent Office2236161► Subscribe
European Patent Office2939696► Subscribe
Spain2569262► Subscribe
Hong Kong1215171► Subscribe
Japan2005506351► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
US Department of Justice
Farmers Insurance
Accenture
Novartis
Teva
Chubb
Fish and Richardson
Deloitte
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot